BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 30880225)

  • 1. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
    J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.
    Lee J; Kim JS; Cho HI; Jo SR; Jang YK
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
    Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM
    J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of histone demethylase KDM4 by ML324 induces apoptosis through the unfolded protein response and Bim upregulation in hepatocellular carcinoma cells.
    Kim SY; Hwang S; Lee BR; Hong JA; Sung YH; Kim I
    Chem Biol Interact; 2022 Feb; 353():109806. PubMed ID: 34999051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
    Wang D; Han S; Peng R; Jiao C; Wang X; Yang X; Yang R; Li X
    J Exp Clin Cancer Res; 2016 Feb; 35():37. PubMed ID: 26911146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
    Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
    Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686.
    Wu BH; Chen H; Cai CM; Fang JZ; Wu CC; Huang LY; Wang L; Han ZG
    Oncotarget; 2016 Feb; 7(6):6847-63. PubMed ID: 26760772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antischistosomal potential of GSK-J4, an H3K27 demethylase inhibitor: insights from molecular modeling, transcriptomics and in vitro assays.
    Lobo-Silva J; Cabral FJ; Amaral MS; Miyasato PA; de Freitas RP; Pereira ASA; Khouri MI; Barbosa MMF; Ramos PIP; Leite LCC; Asojo OA; Nakano E; Verjovski-Almeida S; Farias LP
    Parasit Vectors; 2020 Mar; 13(1):140. PubMed ID: 32178714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of the
    Matthews KA; Senagbe KM; Nötzel C; Gonzales CA; Tong X; Rijo-Ferreira F; Bhanu NV; Miguel-Blanco C; Lafuente-Monasterio MJ; Garcia BA; Kafsack BFC; Martinez ED
    ACS Infect Dis; 2020 May; 6(5):1058-1075. PubMed ID: 32272012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2.
    Shao N; Cheng J; Huang H; Gong X; Lu Y; Idris M; Peng X; Ong BX; Zhang Q; Xu F; Liu C
    Cell Death Dis; 2021 Mar; 12(3):253. PubMed ID: 33692332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
    Tang Q; Hu G; Sang Y; Chen Y; Wei G; Zhu M; Chen M; Li S; Liu R; Peng Z
    Clin Transl Med; 2024 May; 14(5):e1703. PubMed ID: 38769666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma.
    Gong J; Yan S; Yu H; Zhang W; Zhang D
    Med Sci Monit; 2018 Oct; 24():7586-7594. PubMed ID: 30353907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Bioinformatics Analysis of Key Methyltransferases and Demethylases for Histone Lysines in Hepatocellular Carcinoma.
    Zheng Y; Tang L; Chen G; Liu Z
    Technol Cancer Res Treat; 2020; 19():1533033820983284. PubMed ID: 33355042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
    Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
    Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
    Wang L; Chang J; Varghese D; Dellinger M; Kumar S; Best AM; Ruiz J; Bruick R; Peña-Llopis S; Xu J; Babinski DJ; Frantz DE; Brekken RA; Quinn AM; Simeonov A; Easmon J; Martinez ED
    Nat Commun; 2013; 4():2035. PubMed ID: 23792809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
    Bayo J; Fiore EJ; Dominguez LM; Cantero MJ; Ciarlantini MS; Malvicini M; Atorrasagasti C; Garcia MG; Rossi M; Cavasotto C; Martinez E; Comin J; Mazzolini GD
    Gut; 2021 Jul; 70(7):1362-1374. PubMed ID: 33106353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive and Integrative Analysis Reveals the Diagnostic, Clinicopathological and Prognostic Significance of Polo-Like Kinase 1 in Hepatocellular Carcinoma.
    Lin P; Wen DY; Dang YW; He Y; Yang H; Chen G
    Cell Physiol Biochem; 2018; 47(3):925-947. PubMed ID: 29843122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unravelling KDM4 histone demethylase inhibitors for cancer therapy.
    Baby S; Gurukkala Valapil D; Shankaraiah N
    Drug Discov Today; 2021 Aug; 26(8):1841-1856. PubMed ID: 34051367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.